Biocon's MD & CEO Siddharth Mittal On Booming Obesity & Diabetes Drug Market

Biocon's MD & CEO, Siddharth Mittal, discusses the significant growth in the GLP space, focusing on medications for obesity and diabetes. He highlights the success of two peptides launched by U.S. and European companies, with the market projected to reach $100 billion. Siddharth Mittal notes that multiple drugs are currently under trial, and Biocon is also well-positioned in this drug space. He believes this area of medicine can drive growth in the generic business in the upcoming financial year.